trial

Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

NCTId NCT01009060
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 50 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2011-08-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2009-12-01
Primary completion
2011-08-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
GSK239512

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

15 total
Garden Grove, United StatesLos Angeles, United StatesNational City, United StatesSacramento, United StatesSan Diego, United StatesTorrance, United StatesChicago, United StatesIndianapolis, United StatesCatonsville, United StatesBoston, United StatesJamaica Plain, United StatesMount Laurel, United States

Linked catalysts

1
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia — primary completion2011-08-10

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE2
Primary Completion Date
2011-08-10
Status
COMPLETED
relationships
The graph out of here
drug
GSK239512
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication